Medical News

RSS

Sanofi announces results from Phase IIIb ELIXA study of Lyxumia in adults with diabetes and high CV risk

Sanofi announced today the presentation of full results of the Phase IIIb ELIXA study, which was designed to assess the cardiovascular (CV) safety of Lyxumia (lixisenatide) in adults with type 2 diabetes and high CV risk.

8 Jun 2015

Molecular Health, TestAnalytika sign distribution agreement for TreatmentMAP in Latin American region

Molecular Health signed an agreement with TestAnalytika to be its preferred distributor in the Latin American region at the 2015 ASCO Annual Meeting. TestAnalytika will begin to market and distribute Molecular Health's cancer treatment decision support product, TreatmentMAP, to patients, physicians, hospitals, laboratories, cancer centers and insurers in Latin America later this year.

8 Jun 2015

Jazz enrolls first patients in JZP-110 Phase 3 study for treatment of EDS in patients with narcolepsy or OSA

Jazz Pharmaceuticals plc announced today that the first patients have been enrolled in a Phase 3 clinical development program evaluating the safety and efficacy of its investigational drug candidate, JZP-110, as a wake-promoting agent in the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy or with obstructive sleep apnea (OSA).

8 Jun 2015

EMR Direct's phiMail Server software achieves ONC-HIT 2014 Edition Modular Certification

EMR Direct, a Health Information Service Provider (HISP) and leading developer of Direct messaging software for the secure exchange of Protected Health Information (PHI) over the Internet, announced today that its phiMail Server software has achieved Office of the National Coordinator for Health Information Technology (ONC-HIT) 2014 Edition Modular Certification via Drummond Group LLC, an Authorized Certification Body (ACB).

8 Jun 2015

Breathe NIOV System improves exercise duration among patients with chronic respiratory disease

Breathe Technologies, a developer and manufacturer of innovative medical technologies for patients with respiratory insufficiency diseases and neuromuscular diseases, announced new data today demonstrating that use of its Non-Invasive Open Ventilation (NIOV) System in pulmonary rehabilitation was associated with significant improvement in mean exercise duration change (approximately 63 percent) among patients with chronic respiratory disease.

8 Jun 2015

Results from Intarcia's two phase 3 clinical trials of ITCA 650 to be presented at ADA's Scientific Session

Intarcia Therapeutics, Inc. today announced the presentation of results from its first two phase 3 clinical trials (FREEDOM-1 and FREEDOM-1 HBL) of its late-stage investigational candidate ITCA 650 (exenatide delivered continuously via a small matchstick-size subcutaneous osmotic mini-pump just once or twice yearly) at the 75th Scientific Sessions of the American Diabetes Association.

8 Jun 2015

Clinical data of Trovagene's Precision Cancer Monitoring platform to be presented at two medical conferences

Trovagene, Inc., a developer of cell-free molecular diagnostics, announced today that clinical data featuring its Precision Cancer MonitoringSM platform will be presented at the 2015 Cancer Markers and Liquid Biopsies conference in San Diego, CA on June 11-12, and at the AACR Precision Medicine Series: Integrating Clinical Genomics and Cancer Therapy in Salt Lake City, UT on June 13-16.

8 Jun 2015

Celtaxsys closes $40M Series D financing and receives $5M CFFT grant to conduct CTX-4430 Phase 2 trial

Celtaxsys, Inc., a clinical stage drug development company focused on developing novel therapies for inflammatory diseases, today announced the successful completion of a $40M Series D financing led by Domain Partners VIII. Additional investors in the financing include Lumira Capital, RMI Partners, Masters Capital Management and the Georgia Research Alliance Venture Fund.

8 Jun 2015

Merck KGaA, Darmstadt, Germany forms Global Fertility Alliance with Illumina and Genea

Merck KGaA, Darmstadt, Germany, a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials today announced the formation of the Global Fertility Alliance, a new collaboration to advance excellence in fertility technologies and processes within the assisted reproductive treatment (ART) laboratory.

From Illumina, Inc. 8 Jun 2015

DalCor, MHI partner to conduct Phase III clinical trial of investigational cardiovascular drug

DalCor Pharmaceuticals and the Montreal Heart Institute announced today a collaboration in principle to conduct an international Phase III clinical trial which could result in a major clinical advance in cardiovascular personalised medicine.

8 Jun 2015

Researchers report new way to treat T-cell acute lymphoblastic leukemia

Researchers at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center are reporting a potentially important discovery in the battle against one of the most devastating forms of leukemia that accounts for as many as one in five children with a particularly aggressive form of the disease relapsing within a decade.

8 Jun 2015

Washington Healthcare Authority selects UW Medicine ACN as new healthcare option for employees

The UW Medicine Accountable Care Network today announced that the Washington Healthcare Authority has chosen the UW Medicine ACN as a new healthcare option for those enrolled in the Public Employees Benefit Board (PEBB) program. The new option will be available to these employees during the 2015 open enrollment period in November, with coverage beginning January 1, 2016.

8 Jun 2015

People now have powerful new option for relieving dry mouth symptoms

People who suffer from dry mouth, or xerostomia, now have a powerful new option for relieving their symptoms. Building on the success of its antioxidant oral care product line, Dallas-based PerioSciences LLC is launching Dry Mouth AO ProGel and a new MILD formula of its Hydrating AO ProRinse. The new products, along with the established Hydrating AO ProRinse and AO ProToothpaste, provide a complete Hydrating Oral Care System.

8 Jun 2015

New therapeutic target discovered for idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease for which as yet no causal therapy exists. It is, however, known that the lung interstitium - the connective tissue between the air sacs in the lower part of the lung - is affected.

8 Jun 2015

Global RA treatment market expected to increase just over $19 billion by 2020

Analysis from business intelligence provider GBI Research - Rheumatoid Arthritis Market to 2020 - says that the global Rheumatoid Arthritis (RA) treatment market is expected to increase in value, from $14.3 billion in 2013 to just over $19 billion by 2020, at a Compound Annual Growth Rate (CAGR) of 4.1%.

8 Jun 2015

Innovative QI program speeds recovery in patients undergoing colon and rectal operations

Patients undergoing colon and rectal operations who participated in an innovative quality improvement (QI) program to speed their recovery and enhance results experienced shorter hospitalizations, reduced infection rates, and lower hospital costs, according to new study results.

8 Jun 2015

New study gives insight into the mental health of teens, children with Down syndrome

A new study gives insight into the mental health of children and teens with Down syndrome and the behavioral medications that medical caregivers sometimes prescribe for them.

8 Jun 2015

CURE Urgent Care, Mount Sinai Health System expand partnership

CURE Urgent Care, a premier concierge medical practice providing immediate treatment for illness and injuries, is pleased to announce a joint venture with Mount Sinai Health System that further supports the existing relationship between the two entities.

8 Jun 2015

Braeburn reports positive topline results from Probuphine Phase 3 study for treatment of opioid addiction

Braeburn Pharmaceuticals, an Apple Tree Partners company, today reported positive topline results from the Phase 3 double-blind, double-dummy clinical study of Probuphine, the investigational subdermal implant containing buprenorphine HCl for the long-term maintenance treatment of opioid addiction.

8 Jun 2015

Merck Canada announces conditional approval of KEYTRUDA (pembrolizumab) for melanoma treatment

Merck Canada Inc. announced today that KEYTRUDATM (pembrolizumab) was authorized for sale with conditions by Health Canada on May 19, 2015. KEYTRUDA is a humanized monoclonal antibody that works by increasing the ability of the body's immune system to fight advanced melanoma, the most serious form of skin cancer. It is the first of a new class of therapies called anti-PD-1s approved in Canada.

8 Jun 2015

Medical News

Sanofi announces results from Phase IIIb ELIXA study of Lyxumia in adults with diabetes and high CV risk

Molecular Health, TestAnalytika sign distribution agreement for TreatmentMAP in Latin American region

Jazz enrolls first patients in JZP-110 Phase 3 study for treatment of EDS in patients with narcolepsy or OSA

EMR Direct's phiMail Server software achieves ONC-HIT 2014 Edition Modular Certification

Breathe NIOV System improves exercise duration among patients with chronic respiratory disease

Results from Intarcia's two phase 3 clinical trials of ITCA 650 to be presented at ADA's Scientific Session

Clinical data of Trovagene's Precision Cancer Monitoring platform to be presented at two medical conferences

Celtaxsys closes $40M Series D financing and receives $5M CFFT grant to conduct CTX-4430 Phase 2 trial

Merck KGaA, Darmstadt, Germany forms Global Fertility Alliance with Illumina and Genea

DalCor, MHI partner to conduct Phase III clinical trial of investigational cardiovascular drug

Researchers report new way to treat T-cell acute lymphoblastic leukemia

Washington Healthcare Authority selects UW Medicine ACN as new healthcare option for employees

People now have powerful new option for relieving dry mouth symptoms

New therapeutic target discovered for idiopathic pulmonary fibrosis

Global RA treatment market expected to increase just over $19 billion by 2020

Innovative QI program speeds recovery in patients undergoing colon and rectal operations

New study gives insight into the mental health of teens, children with Down syndrome

CURE Urgent Care, Mount Sinai Health System expand partnership

Braeburn reports positive topline results from Probuphine Phase 3 study for treatment of opioid addiction

Merck Canada announces conditional approval of KEYTRUDA (pembrolizumab) for melanoma treatment

How real-time off-gas analysis improves fermentation process control

Advancing Drug Safety Assessment With AI, Predictive Modeling, and Human-Relevant Data

AI-powered analytics and experimental validation

Latest News